Kenvue Inc. (KVUE)

Kenvue will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 14.92B
Net Income (ttm) 2.13B
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About KVUE

Kenvue is the world’s largest pure-play consumer health company by revenue with $15.1 billion in net sales in 2021. We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day. Our differentiated portfolio of iconic brands—including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec and Nicorette—is built for moments that uniquely matter to our consumers and, we believe, drives positive health outcomes... [Read more]

CEO Thibaut Mongon
Employees 22,200
Stock Exchange NYSE
Ticker Symbol KVUE
Full Company Profile

Financial Performance

Financial Statements


J&J spinoff Kenvue files initial public offering

Kenvue Inc. KVUE, , the consumer products unit of Johnson & Johnson JNJ, +1.09% , late Wednesday filed its initial public offering as part of a previously disclosed spinoff plan for the business. Kenv...

Other symbols: JNJ
1 month ago - Market Watch

J&J's consumer health unit Kenvue files for IPO ahead of spin-off

Johnson & Johnson's consumer health unit on Wednesday filed with the U.S. securities regulator to be listed as an independent company, bringing the healthcare conglomerate a step closer to completing ...

Other symbols: JNJ
1 month ago - Reuters